市場調査レポート

商品コード

1519373

潰瘍性大腸炎の市場レポート：タイプ別、疾患タイプ別、分子タイプ別、薬剤タイプ別、投与経路別、流通チャネル別、地域別、2024年～2032年

Ulcerative Colitis Market Report by Type, Disease Type, Molecule Type, Drug Type, Route of Administration, Distribution Channel, and Region 2024-2032

出版日: 2024年07月01日
発行: IMARC
ページ情報: 英文 136 Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF & Excel (Single User License)

USD 2,999 430,566円

レポートPDFおよびExcelを1名のみがご利用頂けるライセンスです。PDFおよびExcelの印刷は一度のみ可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (5 User License)

USD 3,999 574,136円

レポートPDFおよびExcelを同一企業内の5名様までがご利用頂けるライセンスです。PDFおよびExcelの印刷は可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Corporate License)

USD 4,999 717,706円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等の編集は可能ですが、事前にIMARC Services Private Limited社の許可が必要です。PDFおよびExcelの印刷回数に制限はありません。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の潰瘍性大腸炎の市場規模は2023年に78億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに122億米ドルに達し、2024年から2032年の間に5.02％の成長率（CAGR）を示すと予測しています。潰瘍性大腸炎の市場は、疾病の蔓延、治療法の進歩、政府による支援政策、世界の認知度の向上などにより拡大しており、先進地域および発展途上地域における革新的な治療法の需要を牽引しています。

潰瘍性大腸炎の市場分析：

主な市場促進要因世界的に潰瘍性大腸炎の患者数が急増し、炎症性腸疾患の存在に対する認識が高まっていることが、患者の間で革新的な治療法や診断法に対する需要を刺激しています。加えて、技術の進歩、生物学的製剤の拡大、新しい治療法の発明が市場開拓を強化しています。先進国や新興諸国におけるヘルスケアへの支出の増加も市場拡大を促進します。

主な市場動向：潰瘍性大腸炎の治療において、遺伝的、環境的、表現型の特徴に基づいて治療法をカスタマイズする個別化医療を重視する傾向が強まっています。さらに、重症例に対する生物学的製剤やバイオシミラーの採用が増加しており、この市場における製薬業界の方向性に大きな影響を与えています。

地理的動向：北米は、高度なヘルスケア施設、高額な医療費、確立された製薬会社によって潰瘍性大腸炎の市場をリードしています。しかし、アジア太平洋地域は、医療施設の増加、患者の意識向上、中国やインドなどの医療ツーリズムの中心地であることから、かなりの速度で発展すると予想されます。

競合情勢：潰瘍性大腸炎業界の主要市場プレイヤーには、アボット・ラボラトリーズ、AbbVie Inc.、AstraZeneca plc、Bristol-Myers Squibb Company、Eli Lilly and Company、F. Hoffmann-La Roche Ltd.、GlaxoSmithKline plc、Johnson &Johnson、Merck &Co.ファイザー、武田薬品工業、テバ・ファーマシューティカル・インダストリーズなどです。

課題と機会：同市場の主な課題は治療費の高さであり、特に生物学的製剤が関与している場合、低所得国においてアクセスの障壁となる可能性があります。もう一つの要因は、新薬の承認手続きに手間がかかり、時間がかかることで、新しい治療法の市場参入が遅れる可能性があります。課題の深刻さにもかかわらず、この課題はチャンスを生み出す基礎となり得る。費用対効果の高い治療法を開発し、承認プロセスを合理化することは、世界中の企業にとって有益となる可能性があります。

潰瘍性大腸炎の市場動向：

潰瘍性大腸炎の有病率の増加

潰瘍性大腸炎の有病率の増加や炎症性腸疾患の存在に対する認知の広がりは、患者の間で革新的な治療法や診断法に対する需要を刺激しています。さらに、技術の進歩、生物学的製剤の拡大、新しい治療法の発明が市場開拓を強化しています。先進国や新興諸国におけるヘルスケアへの支出の増大も市場拡大を促進します。NATIONAL LIBRARY OF MEDICINEによると、潰瘍性大腸炎の罹患率は10万人あたり年間9～20人。有病率は10万人あたり156～291例/年です。

治療の進歩

潰瘍性大腸炎の治療は、生物学的製剤や低分子医薬品の開発によって大きく進歩しました。この進歩がもたらした前向きな精神は、市場により有利な関連要因を生み出しています。一方では、診断技術の進歩や新しい標的治療法の開拓が、より効果的な治療法の開発による採用の増加により、市場にプラスの影響を与えています。例えば、ファイザー社は2023年、米国食品医薬品局（FDA）が中等症から重症の活動性の潰瘍性大腸炎（UC）の成人患者を対象に、1日1回経口投与の選択的スフィンゴシン-1-リン酸（S1P）受容体モジュレーターであるVELSIPITY（TM）（エトラシモド）を承認したと発表しました。

政府と規制当局の支援

政府の好意的な政策とヘルスケア支出の増加は、潰瘍性大腸炎の市場の成長に大きく影響します。効果的な新薬の迅速な市場参入を促進する規制当局の承認により、患者は先進的な治療オプションを利用できるようになります。さらに、いくつかの政府は研究開発への資金提供を強化し、潰瘍性大腸炎の革新的な治療法への投資を製薬企業に促しており、これが市場の成長をさらに刺激しています。

北米
- 米国
- カナダ
アジア太平洋
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- インドネシア
- その他
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- ロシア
- その他
ラテンアメリカ
- ブラジル
- メキシコ
- その他
中東・アフリカ
- 市場動向
- 市場内訳：国別
- 市場予測

第13章 SWOT分析

概要
強み
弱み
機会
脅威

第14章バリューチェーン分析

第15章ポーターのファイブフォース分析

概要
買い手の交渉力
供給企業の交渉力
競合の程度
新規参入業者の脅威
代替品の脅威

第16章価格分析

第17章競合情勢

市場構造
主要企業
主要企業のプロファイル
- Abbott Laboratories
- AbbVie Inc.
- AstraZeneca plc
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck & Co. Inc.
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.

図表

List of Figures

Figure 1: Global: Ulcerative Colitis Market: Major Drivers and Challenges
Figure 2: Global: Ulcerative Colitis Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Ulcerative Colitis Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Ulcerative Colitis Market: Breakup by Type (in %), 2023
Figure 5: Global: Ulcerative Colitis Market: Breakup by Disease Type (in %), 2023
Figure 6: Global: Ulcerative Colitis Market: Breakup by Molecule Type (in %), 2023
Figure 7: Global: Ulcerative Colitis Market: Breakup by Drug Type (in %), 2023
Figure 8: Global: Ulcerative Colitis Market: Breakup by Route of Administration (in %), 2023
Figure 9: Global: Ulcerative Colitis Market: Breakup by Distribution Channel (in %), 2023
Figure 10: Global: Ulcerative Colitis Market: Breakup by Region (in %), 2023
Figure 11: Global: Ulcerative Colitis (Mild UC) Market: Sales Value (in Million US$), 2018 & 2023
Figure 12: Global: Ulcerative Colitis (Mild UC) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 13: Global: Ulcerative Colitis (Moderate UC) Market: Sales Value (in Million US$), 2018 & 2023
Figure 14: Global: Ulcerative Colitis (Moderate UC) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 15: Global: Ulcerative Colitis (Severe UC) Market: Sales Value (in Million US$), 2018 & 2023
Figure 16: Global: Ulcerative Colitis (Severe UC) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 17: Global: Ulcerative Colitis (Ulcerative Proctitis) Market: Sales Value (in Million US$), 2018 & 2023
Figure 18: Global: Ulcerative Colitis (Ulcerative Proctitis) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 19: Global: Ulcerative Colitis (Proctosigmoiditis) Market: Sales Value (in Million US$), 2018 & 2023
Figure 20: Global: Ulcerative Colitis (Proctosigmoiditis) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 21: Global: Ulcerative Colitis (Left-sided Colitis) Market: Sales Value (in Million US$), 2018 & 2023
Figure 22: Global: Ulcerative Colitis (Left-sided Colitis) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 23: Global: Ulcerative Colitis (Pancolitis or Universal Colitis) Market: Sales Value (in Million US$), 2018 & 2023
Figure 24: Global: Ulcerative Colitis (Pancolitis or Universal Colitis) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 25: Global: Ulcerative Colitis (Fulminant Colitis) Market: Sales Value (in Million US$), 2018 & 2023
Figure 26: Global: Ulcerative Colitis (Fulminant Colitis) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 27: Global: Ulcerative Colitis (Small Molecules) Market: Sales Value (in Million US$), 2018 & 2023
Figure 28: Global: Ulcerative Colitis (Small Molecules) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 29: Global: Ulcerative Colitis (Biologics) Market: Sales Value (in Million US$), 2018 & 2023
Figure 30: Global: Ulcerative Colitis (Biologics) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 31: Global: Ulcerative Colitis (Anti-Inflammatory Drugs) Market: Sales Value (in Million US$), 2018 & 2023
Figure 32: Global: Ulcerative Colitis (Anti-Inflammatory Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 33: Global: Ulcerative Colitis (Anti-TNF Biologics) Market: Sales Value (in Million US$), 2018 & 2023
Figure 34: Global: Ulcerative Colitis (Anti-TNF Biologics) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 35: Global: Ulcerative Colitis (Immunosuppressant) Market: Sales Value (in Million US$), 2018 & 2023
Figure 36: Global: Ulcerative Colitis (Immunosuppressant) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 37: Global: Ulcerative Colitis (Calcineurin Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
Figure 38: Global: Ulcerative Colitis (Calcineurin Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 39: Global: Ulcerative Colitis (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
Figure 40: Global: Ulcerative Colitis (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 41: Global: Ulcerative Colitis (Oral) Market: Sales Value (in Million US$), 2018 & 2023
Figure 42: Global: Ulcerative Colitis (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 43: Global: Ulcerative Colitis (Injectable) Market: Sales Value (in Million US$), 2018 & 2023
Figure 44: Global: Ulcerative Colitis (Injectable) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 45: Global: Ulcerative Colitis (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 46: Global: Ulcerative Colitis (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 47: Global: Ulcerative Colitis (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 48: Global: Ulcerative Colitis (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 49: Global: Ulcerative Colitis (Drug Store) Market: Sales Value (in Million US$), 2018 & 2023
Figure 50: Global: Ulcerative Colitis (Drug Store) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 51: Global: Ulcerative Colitis (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
Figure 52: Global: Ulcerative Colitis (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 53: North America: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
Figure 54: North America: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 55: United States: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
Figure 56: United States: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 57: Canada: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
Figure 58: Canada: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 59: Asia-Pacific: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
Figure 60: Asia-Pacific: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 61: China: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
Figure 62: China: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 63: Japan: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
Figure 64: Japan: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 65: India: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
Figure 66: India: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 67: South Korea: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
Figure 68: South Korea: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 69: Australia: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
Figure 70: Australia: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 71: Indonesia: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
Figure 72: Indonesia: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 73: Others: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
Figure 74: Others: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 75: Europe: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
Figure 76: Europe: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 77: Germany: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
Figure 78: Germany: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 79: France: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
Figure 80: France: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 81: United Kingdom: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
Figure 82: United Kingdom: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 83: Italy: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
Figure 84: Italy: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 85: Spain: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
Figure 86: Spain: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 87: Russia: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
Figure 88: Russia: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 89: Others: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
Figure 90: Others: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 91: Latin America: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
Figure 92: Latin America: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 93: Brazil: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
Figure 94: Brazil: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 95: Mexico: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
Figure 96: Mexico: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 97: Others: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
Figure 98: Others: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 99: Middle East and Africa: Ulcerative Colitis Market: Sales Value (in Million US$), 2018 & 2023
Figure 100: Middle East and Africa: Ulcerative Colitis Market: Breakup by Country (in %), 2023
Figure 101: Middle East and Africa: Ulcerative Colitis Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 102: Global: Ulcerative Colitis Industry: SWOT Analysis
Figure 103: Global: Ulcerative Colitis Industry: Value Chain Analysis
Figure 104: Global: Ulcerative Colitis Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Ulcerative Colitis Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Ulcerative Colitis Market Forecast: Breakup by Type (in Million US$), 2024-2032
Table 3: Global: Ulcerative Colitis Market Forecast: Breakup by Disease Type (in Million US$), 2024-2032
Table 4: Global: Ulcerative Colitis Market Forecast: Breakup by Molecule Type (in Million US$), 2024-2032
Table 5: Global: Ulcerative Colitis Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
Table 6: Global: Ulcerative Colitis Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
Table 7: Global: Ulcerative Colitis Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
Table 8: Global: Ulcerative Colitis Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 9: Global: Ulcerative Colitis Market: Competitive Structure
Table 10: Global: Ulcerative Colitis Market: Key Players

Product Code: SR112024A5663

The global ulcerative colitis market size reached US$ 7.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.2 Billion by 2032, exhibiting a growth rate (CAGR) of 5.02% during 2024-2032. The ulcerative colitis market is expanding due to rising disease prevalence, advancements in medical treatments, supportive government policies, and increasing global awareness, which drive the demand for innovative therapies in developed and developing regions.

Ulcerative Colitis Market Analysis:

Major Market Drivers: The surging number of ulcerative colitis globally, and the awareness about the existence of inflammatory bowel diseases, stimulate the demand for innovative treatments and diagnostic methods among patients. In addition, technological progress, the expansion of biologics and the invention of new therapies intensify market development. The growing expenditure on healthcare in developed and developing countries also promotes market enlargement.

Key Market Trends: There is an increasing trend toward personalized medicine in treating ulcerative colitis, emphasizing customized therapeutic methods based on genetic, environmental, and phenotypic characteristics. Furthermore, the increased adoption of biologics and biosimilars for managing severe cases is significantly influencing the direction of the pharmaceutical industry in this market.

Geographical Trends: North America leads the ulcerative colitis market due to advanced healthcare facilities, high healthcare expenditure, and established pharmaceutical companies. However, Asia Pacific is anticipated to develop at a significant rate, given the increased health facilities, patient awareness, and medical tourism centering the region, such as China and India.

Competitive Landscape: Some of the major market players in the ulcerative colitis industry include Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd. among many others.

Challenges and Opportunities: The primary challenge of the market is the high cost of treatment, which may create barriers to access in low-income countries, particularly when biologics are involved. Another factor is the labor-intensive and lengthy drug approval process, which could delay new treatments from entering the market. Despite its severity, the challenge can serve as a basis for opportunities. Developing cost-effective therapies and streamlining the approval process can become beneficial for businesses across the globe.

Ulcerative Colitis Market Trends:

Increasing Prevalence of Ulcerative Colitis

The growth in the prevalence of ulcerative colitis, as well as the spread of awareness about the existence of inflammatory bowel diseases, stimulates the demand for innovative treatments and diagnostic methods among patients. In addition, technological progress, the expansion of biologics, and the invention of new therapies intensify market development. The growing expenditure on healthcare in developed and developing countries also promotes market enlargement. According to the NATIONAL LIBRARY OF MEDICINE, ulcerative colitis has an incidence of 9 to 20 cases per 100,000 persons per year. Its prevalence is 156 to 291 cases per 100,000 persons per year.

Advancements in Medical Treatments

Medical treatment of ulcerative colitis has come a long way with the development of biologics and small-molecule drugs. The positive spirit brought about by this progress has created more favorable market-related factors. On the one hand, advances in diagnostic technologies and the development of new targeted treatment approaches have positively affected the market due to increased adoption driven by the development of more effective treatments. For instance, Pfizer Inc. in 2023 announced that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY(TM) (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC).

Government and Regulatory Support

Favorable government policies and increased healthcare spending significantly impact the ulcerative colitis market growth. With regulatory approvals facilitating the rapid market entry of new and effective drugs, patients gain access to advanced treatment options. Additionally, several governments have ramped up funding for research and development, encouraging pharmaceutical companies to invest in innovative therapies for ulcerative colitis, which further stimulates market growth.

Ulcerative Colitis Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on type, disease type, molecule type, drug type, route of administration, and distribution channel.

Breakup by Type:

Mild UC

Moderate UC

Severe UC

Mild UC accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the type. This includes mild UC, moderate UC, and severe UC. According to the report, mild UC represented the largest segment.

The mild ulcerative colitis segment dominates owing to the greater prevalence of mild cases compared to moderate and severe forms. Patients with mild UC generally experience fewer symptoms, which can typically be managed with oral medications, such as aminosalicylates. It benefits from numerous first-line treatment options that are less expensive and have fewer side effects, making them accessible and favored by patients and healthcare providers. The availability of effective and affordable treatments contributes significantly to the dominance of this segment in increasing the overall ulcerative colitis market demand. Mild ulcerative colitis is treated with mesalamine (5-aminosalicylic acid, 5-ASA) and other UC medications across all countries. As per the American College of Gastroenterology (ACG) treatment instruction, ulcerative colitis (UC) is categorized as mild in patients who have fewer than four (4) bowel movements per day, minimal bleeding, and no appreciable urgency or abdominal pain. In comparative studies of 2.4 g and 4.8 g daily doses of mesalamine, it was found that patients with mild disease will improve with 2.4 g and 4.8 g doses of mesalamine.

Breakup by Disease Type:

Ulcerative Proctitis

Proctosigmoiditis

Left-sided Colitis

Pancolitis or Universal Colitis

Fulminant Colitis

Ulcerative proctitis holds the largest share in the industry

A detailed breakup and analysis of the market based on the disease type have also been provided in the report. This includes ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis or universal colitis, and fulminant colitis. According to the report, ulcerative proctitis accounted for the largest market share.

Ulcerative proctitis is considered the mildest due to the inflammation being confined to the rectum. Patients usually experience such symptoms as rectal bleeding, urgency, and tenesmus. As per the study by Matthew Mutch, in Shackelford's Surgery of the Alimentary Tract, 2 Volume Set (Eighth Edition), 2019, patients with ulcerative pancolitis for more than 8 years are at higher risk of colorectal cancer, with the risk ranging from 0.5% to 1% per year. The localized nature of symptoms is why it is easier to treat the condition with medicines that require the closest interaction with the perished area rather than using more invasive and less patient-friendly systemic treatment. The focused treatment combines fewer systemic side effects, which is why patients prefer using suppositories or enemas as treatment. Facing better treatment opportunities, patients with ulcerative proctitis have a very good prognosis. Hence, the demand for quality treatments is growing.

Breakup by Molecule Type:

Small Molecules

Biologics

Biologics represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the molecule type. This includes small molecules and biologics. According to the report, biologics represented the largest segment.

Biologics represent the largest segment in the market. The key reasons for the popularity of this therapy type involve its high efficiency in reducing inflammation and achieving and maintaining remission in patients suffering from moderate to severe disease. These protein-containing drugs work by aiming at particular parts of the immune system that encourage developing inflammation in the body. The increasing demand for biologics is explained by the growing number of approvals and biosimilars, which will make these drugs more available and less costly. For illustration purposes, in March 2024, Johnson & Johnson unveiled the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration pursuing approval of TREMFYA(R) (guselkumab) to treat adult patients with moderately to severely active ulcerative colitis. It is supported by data from the Phase 3 QUASAR program evaluating the efficacy and safety of TREMFYA(R) to treat patients with moderately to severely active UC who had an inadequate response or intolerance to traditional therapy, prior biologics and/or JAK inhibitors.

Breakup by Drug Type:

Anti-Inflammatory Drugs

Anti-TNF Biologics

Immunosuppressant

Calcineurin Inhibitors

Others

Anti-TNF biologics exhibits a clear dominance in the market

A detailed breakup and analysis of the market based on the drug type have also been provided in the report. This includes anti-inflammatory drugs, anti-TNF biologics, immunosuppressant, calcineurin inhibitors, and others. According to the report, anti-TNF biologics accounted for the largest market share.

The market is currently dominated by anti-TNF biologics, primarily due to their ability to control inflammation and sustain remission in patients with moderate-to-severe conditions. Anti-TNF biologics are accustomed to neutralizing the action of a protein in the body known as TNF that causes inflammation, making them a preferable option for patients who are not treated with monotherapy. In addition, the established success of anti-TNF biologics in patient quality of life would agree with these results, despite concerns about costs and side effects.

Breakup by Route of Administration:

Oral

Injectable

Injectable dominates the market

The report has provided a detailed breakup and analysis of the market based on the route of administration. This includes oral and injectable. According to the report, injectables represented the largest segment.

Injectable medications hold a prominent position in the ulcerative colitis market revenue, primarily due to their capacity to deliver treatments directly to the bloodstream, effectively bypassing the digestive system. This category includes biologics such as infliximab and adalimumab, which are particularly used for moderate to severe cases. The preference for injectables stems from their rapid action and high efficacy, especially beneficial for patients who do not respond to oral medications. Additionally, the less frequent dosing requirement compared to oral medications enhances the appeal of injectables, making them a popular choice in managing ulcerative colitis and contributing to their substantial market share. Top of FormFor instance, in 2023, the Food and Drug Administration (FDA) indicated that the subcutaneous administration of vedolizumab is an approvable maintenance therapy for moderate to severe ulcerative colitis following intravenous infusion. It is the only FDA-approved biologic in ulcerative colitis maintenance therapy that is based on IV and SC dose-approved medication.

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Drug Store

Others

Hospital pharmacies are the predominant market segment

A detailed breakup and analysis of the market based on the distribution channel have also been provided in the report. This includes hospital pharmacies, retail pharmacies, drug store, and others. According to the report, hospital pharmacies accounted for the largest market share.

Hospital pharmacies constitute the largest segment in the ulcerative colitis market forecast. Their pivotal role in distributing treatments stems from their proximity to patient care settings and their responsibilities in administering and monitoring therapies. Hospitals are often the first to receive new drug approvals, positioning them as primary channels for distributing advanced therapeutics. This segment benefits from direct interactions with pharmaceutical manufacturers and often engages in price negotiations, which can significantly influence treatment accessibility and adoption rates among patients. For instance, the Apollo Hospital pharmacy business is about to touch 10,000 crore in revenue this year with 5,790 pharmacies, Apollo is the largest pharmacy chain, adding 400-500 stores each year.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest ulcerative colitis market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America dominates the ulcerative colitis market on account of the high occurrence of the disorder, superior medical facilities, and extensive funding for R&D activities. The American and Canadian health systems ensure the substantial usage of progressive treatments, and private insurance plans and campaigns further enhance the consumer understanding of products. Companies in the pharmaceutical and biotech sectors accelerate the development of innovative treatment methods. They integrate the most successful ones into their treatment protocols at an early stage, advancing the market. At present, ulcerative colitis has an incidence of 9 to 20 cases per 100,000 persons per year and 156 to 291 cases per 100,000 persons per year as per National Institute of Health (NIH). Ulcerative colitis market recent opportunities include numerous key players collaborating to expand their market growth. For instance, Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceuticals Industries Ltd., and Sanofi collaborated to create and co-commercialize asset TEV'574, to treat Ulcerative Colitis and Crohn's Disease.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the keyword industry include Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Leading players in the ulcerative colitis market recent developments include the development of advanced biologics and small molecule therapies, improved drug delivery systems, and expansion into untapped markets. The leading players are also involved in strategic initiatives such as partnerships, mergers, acquisitions, and increasing investment in research and innovation to enhance treatment efficacies. These efforts are aimed at boosting market share and addressing the unmet needs in ulcerative colitis management. Besides this, Pfizer Inc. unveiled that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for VELSIPITY(TM) (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator. This medication is intended for the treatment of patients aged 16 and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biological agent.

Latest News:

November 2021: Bristol Myers Squibb received European Commission approval for Zeposia (ozanimod) for the treatment of adults with moderately to severely active ulcerative colitis.Top of Form

March 2024: AbbVie Inc., and Landos Biopharma Inc. unveiled that AbbVie entered into a definitive agreement that provides for the acquisition of Landos, a clinical-stage biopharmaceutical corporation keen on developing advanced novel oral therapeutics for individuals with autoimmune disorders.

Key Questions Answered in This Report:

How has the global ulcerative colitis market performed so far, and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global ulcerative colitis market?
What is the impact of each driver, restraint, and opportunity on the global ulcerative colitis market?
What are the key regional markets?
Which countries represent the most attractive ulcerative colitis market?
What is the breakup of the market based on the type?
Which is the most attractive type in the ulcerative colitis market?
What is the breakup of the market based on the disease type?
Which is the most attractive disease type in the ulcerative colitis market?
What is the breakup of the market based on the molecule type?
Which is the most attractive molecule type in the ulcerative colitis market?
What is the breakup of the market based on the drug type?
Which is the most attractive drug type in the ulcerative colitis market?
What is the breakup of the market based on the route of administration?
Which is the most attractive route of administration in the ulcerative colitis market?
What is the breakup of the market based on the distribution channel?
Which is the most attractive distribution channel in the ulcerative colitis market?
What is the competitive structure of the market?
Who are the key players/companies in the global ulcerative colitis market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Ulcerative Colitis Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Type

6.1 Mild UC
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Moderate UC
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Severe UC
- 6.3.1 Market Trends
- 6.3.2 Market Forecast

7 Market Breakup by Disease Type

7.1 Ulcerative Proctitis
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Proctosigmoiditis
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Left-sided Colitis
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Pancolitis or Universal Colitis
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Fulminant Colitis
- 7.5.1 Market Trends
- 7.5.2 Market Forecast

8 Market Breakup by Molecule Type

8.1 Small Molecules
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Biologics
- 8.2.1 Market Trends
- 8.2.2 Market Forecast

9 Market Breakup by Drug Type

9.1 Anti-Inflammatory Drugs
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Anti-TNF Biologics
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Immunosuppressant
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
9.4 Calcineurin Inhibitors
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
9.5 Others
- 9.5.1 Market Trends
- 9.5.2 Market Forecast

10 Market Breakup by Route of Administration

10.1 Oral
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
10.2 Injectable
- 10.2.1 Market Trends
- 10.2.2 Market Forecast

11 Market Breakup by Distribution Channel

11.1 Hospital Pharmacies
- 11.1.1 Market Trends
- 11.1.2 Market Forecast
11.2 Retail Pharmacies
- 11.2.1 Market Trends
- 11.2.2 Market Forecast
11.3 Drug Store
- 11.3.1 Market Trends
- 11.3.2 Market Forecast
11.4 Others
- 11.4.1 Market Trends
- 11.4.2 Market Forecast

12 Market Breakup by Region

12.1 North America
- 12.1.1 United States
  - 12.1.1.1 Market Trends
  - 12.1.1.2 Market Forecast
- 12.1.2 Canada
  - 12.1.2.1 Market Trends
  - 12.1.2.2 Market Forecast
12.2 Asia-Pacific
- 12.2.1 China
  - 12.2.1.1 Market Trends
  - 12.2.1.2 Market Forecast
- 12.2.2 Japan
  - 12.2.2.1 Market Trends
  - 12.2.2.2 Market Forecast
- 12.2.3 India
  - 12.2.3.1 Market Trends
  - 12.2.3.2 Market Forecast
- 12.2.4 South Korea
  - 12.2.4.1 Market Trends
  - 12.2.4.2 Market Forecast
- 12.2.5 Australia
  - 12.2.5.1 Market Trends
  - 12.2.5.2 Market Forecast
- 12.2.6 Indonesia
  - 12.2.6.1 Market Trends
  - 12.2.6.2 Market Forecast
- 12.2.7 Others
  - 12.2.7.1 Market Trends
  - 12.2.7.2 Market Forecast
12.3 Europe
- 12.3.1 Germany
  - 12.3.1.1 Market Trends
  - 12.3.1.2 Market Forecast
- 12.3.2 France
  - 12.3.2.1 Market Trends
  - 12.3.2.2 Market Forecast
- 12.3.3 United Kingdom
  - 12.3.3.1 Market Trends
  - 12.3.3.2 Market Forecast
- 12.3.4 Italy
  - 12.3.4.1 Market Trends
  - 12.3.4.2 Market Forecast
- 12.3.5 Spain
  - 12.3.5.1 Market Trends
  - 12.3.5.2 Market Forecast
- 12.3.6 Russia
  - 12.3.6.1 Market Trends
  - 12.3.6.2 Market Forecast
- 12.3.7 Others
  - 12.3.7.1 Market Trends
  - 12.3.7.2 Market Forecast
12.4 Latin America
- 12.4.1 Brazil
  - 12.4.1.1 Market Trends
  - 12.4.1.2 Market Forecast
- 12.4.2 Mexico
  - 12.4.2.1 Market Trends
  - 12.4.2.2 Market Forecast
- 12.4.3 Others
  - 12.4.3.1 Market Trends
  - 12.4.3.2 Market Forecast
12.5 Middle East and Africa
- 12.5.1 Market Trends
- 12.5.2 Market Breakup by Country
- 12.5.3 Market Forecast

13 SWOT Analysis

13.1 Overview
13.2 Strengths
13.3 Weaknesses
13.4 Opportunities
13.5 Threats

14 Value Chain Analysis

15 Porters Five Forces Analysis

15.1 Overview
15.2 Bargaining Power of Buyers
15.3 Bargaining Power of Suppliers
15.4 Degree of Competition
15.5 Threat of New Entrants
15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

17.1 Market Structure
17.2 Key Players
17.3 Profiles of Key Players
- 17.3.1 Abbott Laboratories
  - 17.3.1.1 Company Overview
  - 17.3.1.2 Product Portfolio
  - 17.3.1.3 Financials
  - 17.3.1.4 SWOT Analysis
- 17.3.2 AbbVie Inc.
  - 17.3.2.1 Company Overview
  - 17.3.2.2 Product Portfolio
  - 17.3.2.3 Financials
  - 17.3.2.4 SWOT Analysis
- 17.3.3 AstraZeneca plc
  - 17.3.3.1 Company Overview
  - 17.3.3.2 Product Portfolio
  - 17.3.3.3 Financials
  - 17.3.3.4 SWOT Analysis
- 17.3.4 Bristol-Myers Squibb Company
  - 17.3.4.1 Company Overview
  - 17.3.4.2 Product Portfolio
  - 17.3.4.3 Financials
  - 17.3.4.4 SWOT Analysis
- 17.3.5 Eli Lilly and Company
  - 17.3.5.1 Company Overview
  - 17.3.5.2 Product Portfolio
  - 17.3.5.3 Financials
  - 17.3.5.4 SWOT Analysis
- 17.3.6 F. Hoffmann-La Roche Ltd.
  - 17.3.6.1 Company Overview
  - 17.3.6.2 Product Portfolio
  - 17.3.6.3 Financials
- 17.3.7 GlaxoSmithKline plc
  - 17.3.7.1 Company Overview
  - 17.3.7.2 Product Portfolio
  - 17.3.7.3 Financials
  - 17.3.7.4 SWOT Analysis
- 17.3.8 Johnson & Johnson
  - 17.3.8.1 Company Overview
  - 17.3.8.2 Product Portfolio
  - 17.3.8.3 Financials
  - 17.3.8.4 SWOT Analysis
- 17.3.9 Merck & Co. Inc.
  - 17.3.9.1 Company Overview
  - 17.3.9.2 Product Portfolio
  - 17.3.9.3 Financials
  - 17.3.9.4 SWOT Analysis
- 17.3.10 Pfizer Inc.
  - 17.3.10.1 Company Overview
  - 17.3.10.2 Product Portfolio
  - 17.3.10.3 Financials
  - 17.3.10.4 SWOT Analysis
- 17.3.11 Takeda Pharmaceutical Company Limited
  - 17.3.11.1 Company Overview
  - 17.3.11.2 Product Portfolio
  - 17.3.11.3 Financials
  - 17.3.11.4 SWOT Analysis
- 17.3.12 Teva Pharmaceutical Industries Ltd.
  - 17.3.12.1 Company Overview
  - 17.3.12.2 Product Portfolio
  - 17.3.12.3 Financials
  - 17.3.12.4 SWOT Analysis

潰瘍性大腸炎の市場レポート：タイプ別、疾患タイプ別、分子タイプ別、薬剤タイプ別、投与経路別、流通チャネル別、地域別、2024年～2032年

Ulcerative Colitis Market Report by Type, Disease Type, Molecule Type, Drug Type, Route of Administration, Distribution Channel, and Region 2024-2032

潰瘍性大腸炎の市場分析：

潰瘍性大腸炎の市場動向：

目次

第1章 序文

第2章 調査範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界の潰瘍性大腸炎市場

第6章 市場内訳：タイプ別

第7章 市場内訳：疾患タイプ別

第8章 市場内訳：分子タイプ別

第9章 市場内訳：薬剤タイプ別

第10章 市場内訳：投与経路別

第11章 市場内訳：流通チャネル別

第12章 市場内訳：地域別

第13章 SWOT分析

第14章 バリューチェーン分析

第15章 ポーターのファイブフォース分析

第16章 価格分析

第17章 競合情勢

List of Figures

List of Tables

Ulcerative Colitis Market Analysis:

Ulcerative Colitis Market Trends:

Ulcerative Colitis Industry Segmentation:

Breakup by Type:

Breakup by Disease Type:

Breakup by Molecule Type:

Breakup by Drug Type:

Breakup by Route of Administration:

Breakup by Distribution Channel:

Breakup by Region:

Competitive Landscape:

Latest News:

Key Questions Answered in This Report:

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Ulcerative Colitis Market

6 Market Breakup by Type

7 Market Breakup by Disease Type

8 Market Breakup by Molecule Type

9 Market Breakup by Drug Type

10 Market Breakup by Route of Administration

11 Market Breakup by Distribution Channel

12 Market Breakup by Region

13 SWOT Analysis

14 Value Chain Analysis

15 Porters Five Forces Analysis

16 Price Analysis

17 Competitive Landscape

第1章序文

第2章調査範囲と調査手法

第3章エグゼクティブサマリー

第4章イントロダクション

第5章世界の潰瘍性大腸炎市場

第6章市場内訳：タイプ別

第7章市場内訳：疾患タイプ別

第8章市場内訳：分子タイプ別

第9章市場内訳：薬剤タイプ別

第10章市場内訳：投与経路別

第11章市場内訳：流通チャネル別

第12章市場内訳：地域別

第14章バリューチェーン分析

第15章ポーターのファイブフォース分析

第16章価格分析

第17章競合情勢